Vemurafenib and Radiosensitization [PDF]
JAMA Dermatology, 2013 The BRAF inhibitor, vemurafenib, was recently approved for the treatment of patients with BRAFV600 metastatic melanoma. Wider use of this drug and longer follow-up periods of treatment are resulting in the emergence of a growing number of reports detailing new adverse effects.
Lise, Boussemart +8 more
openaire +2 more sources
Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers
Biomedicines, 2022 Radiation therapy plays an important role in almost every cancer treatment. However, radiation toxicity to normal tissues, mainly due to the generation of reactive free radicals, has limited the efficacy of radiotherapy in clinical practice. Curcumin has
Vasiliki Zoi +4 more
doaj +1 more source
Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. [PDF]
, 2016 Tumor hypoxia, a common feature occurring in nearly all human solid tumors is a major contributing factor for failures of anticancer therapies. Because ionizing radiation depends heavily on the presence of molecular oxygen to produce cytotoxic effect ...
Beom Ju Hong +5 more
core +1 more source
Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study. [PDF]
PLoS ONE, 2018 INTRODUCTION:To increase the efficacy of chemoradiation and decrease its toxicity in normal tissue, a new concept is proposed, local radiosensitizer delivery, which combines triggered release of a radiosensitizer from thermosensitive liposomes with local
Helena C Besse +5 more
doaj +1 more source
Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy
Pharmaceutics, 2022 Cancer is responsible for a significant proportion of death all over the world. Therefore, strategies to improve its treatment are highly desired. The use of nanocarriers to deliver anticancer treatments has been extensively investigated and improved ...
Eliza Rocha Gomes +1 more
doaj +1 more source
Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. [PDF]
, 2017 Albendazole is an anti-helminthic drug that has been shown to exhibit anti-cancer properties, however its activity in head and neck squamous cell cancer (HNSCC) was unknown.
Barrett, John W +17 more
core +1 more source
Radio-chemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity [PDF]
, 2002 Background: The standard therapy for patients with clinically resectable rectal cancer is generally considered to be surgery, If the patient is diagnosed with advanced disease, postoperative radiochemotherapy (RCT) is usually recommended. In our study we
Dühmke, Eckhart +4 more
core +1 more source
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
Biomedicines, 2022 Glioblastoma (GBM) is an aggressive primary brain tumor that is associated with a poor prognosis and quality of life. The standard of care has changed minimally over the past two decades and currently consists of surgery followed by radiotherapy (RT ...
Jennifer K. Matsui +11 more
doaj +1 more source
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. [PDF]
, 2016 BackgroundThe tumor-specific microregional effects of the anticancer agent RRx-001, a novel epigenetic-based radio/chemosensitizer with nitrogen oxide-donating properties in phase II clinical trials, were investigated with whole tissue section ...
Cabrales, Pedro +3 more
core +2 more sources
Molecular Oncology, EarlyView.We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu +10 more
wiley +1 more source